This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mungamuri, S. K. Articles by Somasundaram, K. Search for Related Content PubMed PubMed Citation Articles by Mungamuri, S. K. Articles by Somasundaram, K.

Survival Signaling by Notch1: Mammalian Target of Rapamycin (mTOR)–Dependent Inhibition of p53

¹ Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India and ² Department of Pathology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma

Requests for reprints: Kumaravel Somasundaram, Department of Microbiology and Cell Biology, Indian Institute of Science, Sir C.V. Raman Road, Bangalore, Karnataka, India 560012. Phone: 91-80-22932973; Fax: 91-80-23602697; E-mail: skumar{at}mcbl.iisc.ernet.in.

Notch signaling is believed to promote cell survival in general. However, the mechanism is not clearly understood. Here, we show that cells expressing intracellular domain of human Notch1 (NIC-1) are chemoresistant in a wild-type p53-dependent manner. NIC-1 inhibited p53 by inhibiting its activating phosphorylations at Ser¹⁵, Ser²⁰, and Ser³⁹² as well as nuclear localization. In addition, we found that inhibition of p53 by NIC-1 mainly occurs through mammalian target of rapamycin (mTOR) using phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway as the mTOR inhibitor, rapamycin treatment abrogated NIC-1 inhibition of p53 and reversed the chemoresistance. Consistent with this, rapamycin failed to reverse NIC-1-induced chemoresistance in cells expressing rapamycin-resistant mTOR. Further, ectopic expression of eukaryotic initiation factor 4E (eIF4E), a translational regulator that acts downstream of mTOR, inhibited p53-induced apoptosis and conferred protection against p53-mediated cytotoxicity to similar extent as that of NIC-1 overexpression but was not reversed by rapamycin, which indicates that eIF4E is the major target of mTOR in Notch1-mediated survival signaling. Finally, we show that MCF7 (breast cancer) and MOLT4 (T-cell acute lymphoblastic leukemia) cells having aberrant Notch1 signaling are chemoresistant, which can be reversed by both PI3K and mTOR inhibitors. These results establish that Notch1 signaling confers chemoresistance by inhibiting p53 pathway through mTOR-dependent PI3K-Akt/PKB pathway and imply that p53 status perhaps is an important determinant in combination therapeutic strategies, which use mTOR inhibitors and chemotherapy. (Cancer Res 2006; 66(9): 4715-24)

This article has been cited by other articles:

				O. Meurette, S. Stylianou, R. Rock, G. M. Collu, A. P. Gilmore, and K. Brennan Notch Activation Induces Akt Signaling via an Autocrine Loop to Prevent Apoptosis in Breast Epithelial Cells Cancer Res., June 15, 2009; 69(12): 5015 - 5022. [Abstract] [Full Text] [PDF]

				K. Bansal, Y. Narayana, S. A. Patil, and K. N. Balaji M. bovis BCG induced expression of COX-2 involves nitric oxide-dependent and -independent signaling pathways J. Leukoc. Biol., May 1, 2009; 85(5): 804 - 816. [Abstract] [Full Text] [PDF]

				P. Secchiero, E. Melloni, M. G. di Iasio, M. Tiribelli, E. Rimondi, F. Corallini, V. Gattei, and G. Zauli Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism Blood, April 30, 2009; 113(18): 4300 - 4308. [Abstract] [Full Text] [PDF]

				R. D. Meng, C. C. Shelton, Y.-M. Li, L.-X. Qin, D. Notterman, P. B. Paty, and G. K. Schwartz {gamma}-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity Cancer Res., January 15, 2009; 69(2): 573 - 582. [Abstract] [Full Text] [PDF]

				M. R. Bhonde, R. D. Gupte, S. D. Dadarkar, M. G. Jadhav, A. A. Tannu, P. Bhatt, D. R. Bhatia, N. K. Desai, V. Deore, N. Yewalkar, et al. A novel mTOR inhibitor is efficacious in a murine model of colitis Am J Physiol Gastrointest Liver Physiol, December 1, 2008; 295(6): G1237 - G1245. [Abstract] [Full Text] [PDF]

				C. J. Lee, J. Dosch, and D. M. Simeone Pancreatic Cancer Stem Cells J. Clin. Oncol., June 10, 2008; 26(17): 2806 - 2812. [Abstract] [Full Text] [PDF]

				Y. Narayana and K. N. Balaji NOTCH1 Up-regulation and Signaling Involved in Mycobacterium bovis BCG-induced SOCS3 Expression in Macrophages J. Biol. Chem., May 2, 2008; 283(18): 12501 - 12511. [Abstract] [Full Text] [PDF]

				K. T. Leung, K. K.-H. Li, S. S.-M. Sun, P. K. S. Chan, V. E.-C. Ooi, and L. C.-M. Chiu Activation of the JNK pathway promotes phosphorylation and degradation of BimEL--a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia Carcinogenesis, March 1, 2008; 29(3): 544 - 551. [Abstract] [Full Text] [PDF]

				K. G. Leong, K. Niessen, I. Kulic, A. Raouf, C. Eaves, I. Pollet, and A. Karsan Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin J. Exp. Med., November 26, 2007; 204(12): 2935 - 2948. [Abstract] [Full Text] [PDF]

				V. Bolos, J. Grego-Bessa, and J. L. de la Pompa Notch Signaling in Development and Cancer Endocr. Rev., May 1, 2007; 28(3): 339 - 363. [Abstract] [Full Text] [PDF]

				K. Lefort, A. Mandinova, P. Ostano, V. Kolev, V. Calpini, I. Kolfschoten, V. Devgan, J. Lieb, W. Raffoul, D. Hohl, et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCK{alpha} kinases Genes & Dev., March 1, 2007; 21(5): 562 - 577. [Abstract] [Full Text] [PDF]